Journal of Vaccines & Vaccination

Department of Physiology, Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran

Biography

Mehdi Nematbakhsh is currently working as a Professor in the Department of Hematologist. Mehdi Nematbakhsh has authored of many research articles/books related to Medicine.Mehdi Nematbakhsh is serving as an editorial member and reviewer of several international reputed journals. Mehdi Nematbakhsh has successfully completed his Administrative responsibilities. His research interests includes Medicine

Publications

• Research Article   
  Bicelin (B-Cell Lymphoma 2 Inhibitor) a Highly Safe DNA-based Anti-Cancer Drug Showed no in vivo Cytopenia, Nephrotoxicity and Hepatotoxicity
  Author(s): Reza Sheikhnejad*, Farzaneh Ashrafi, Ardeshir Talebi, Bahar Mazaheri, Fatemeh Moslemi and Mehdi Nematbakhsh
  
  Background: Non-Hodgkin's lymphoma is the seventh most common cancer in clinic. Lymphoma could be treated with newly developed anti-apoptotic small molecule inhibitors of bcl-2 such as ABT-199 or venetoclax. However most small molecules present numerous side effects and cancer becomes resistance to them rapidly. PNT100 is a DNA- based bcl-2 inhibitor that has shown great efficacy and safety in treating non-Hodgkin's lymphoma tumors. However, liposomal carrier (smarticles) that was used to deliver PNT100 eventually failed to produce robust efficacy in the latest clinical trial conducted by ProNai Therapeutics (now called Sierra Technology). The high cost of liposomal carriers, makes this targeted drug less affordable. In addition, the liposomal components may also present some minor side effects as reported in pilot phase II trial. In this study, w.. View more»
  

  DOI: 10.35248/2157-7560.21.12.451

  Abstract HTML PDF